Group 1 - Kane Biotech Inc. has completed a non-brokered private placement offering, issuing 12,000,000 common shares at a price of $0.10 per share, resulting in gross proceeds of $1,200,000 [2] - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2] - The company has also secured an unsecured loan of $1,000,000 from an insider, which is interest-free and repayable on demand [3] Group 2 - The transactions are classified as "related party transactions" under Multilateral Instrument 61-101, with the company exempt from formal valuation and minority approval requirements [4] - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which contribute to antibiotic resistance and complicate wound healing [6]

WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announced its fourth quarter and full year 2024 financial results. Fourth Quarter 2024 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended December 31,2024 was $125,859 compared to $57,788 in the three months ended December 31, 2023. Fourth quarter revenue consists primarily of con ...